WP
PRQR icon

Woodline Partners’s ProQR Therapeutics PRQR Stock Holding History

Woodline Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-92,140
Closed -$196K – 1097
2025
Q3 		$196K Sell
92,140
-1,411,860
-94% -$3.08M ﹤0.01% 863
2025
Q2 		$3.07M Buy
1,504,000
+178,345
+13% +$290K 0.02% 653
2025
Q1 		$1.76M Sell
1,325,655
-2,231,346
-63% -$4.75M 0.01% 683
2024
Q4 		$9.43M Buy
+3,557,001
New +$11.3M 0.06% 358

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Woodline Partners's PRQR Position: Q4 2025 in Review

Woodline Partners sold out of ProQR Therapeutics (PRQR) in Q4 2025, closing a stake of 92,140 shares — an estimated $196K sold.

Woodline Partners first reported a position in PRQR in Q4 2024 and held it in 4 quarters. The position peaked at $9.43M in Q4 2024. 65 funds tracked by Wall St. Rank hold PRQR as of Q4 2025.

  • Woodline Partners reported no remaining ProQR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Woodline Partners sold 92,140 ProQR Therapeutics shares in Q4 2025, an estimated $196K.
  • Woodline Partners first reported a position in ProQR Therapeutics in Q4 2024 and held it in 4 quarters.
  • Woodline Partners's ProQR Therapeutics position peaked at $9.43M in Q4 2024.
  • 65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2025.

Based on Woodline Partners's 13F filing for Q4 2025, filed 17 Feb 2026.